Search Results

This of its full year results, with the in the United States which will support CSL's growing R&D appointment highlights CSL's briefing materials released to portfolio including the next-generation mRNA technology long-term commitment to the ASX on 15 August 2023.

On-market purchases under the plan were made twice yearly, following the announcement of CSL's half and full year results Additional shares may be purchased by NEDs on-market at prevailing share prices in accordance with CSL's Securities Dealing Policy Post-Employment Benefits Superannuation contributions are made in accordance with legislation and are included in the reported base fee, and are not additional to the base fee.

On 17 August 2016, CSL announced its full year results for Esterase Inhibitor Subcutaneous (Human)) had been (b) of this Directors' Report.

Shares are purchased by NEDs on-market consideration of eight Global Biopharmaceutical companies of at prevailing share prices, twice yearly, after the announcement of CSL's half and full year results.

2025 CSL's Businesses and Outlook 16 Governance 11 February - Half Year results and interim dividend announcement Innovation Governance 56 Shares trade ex-dividend 10 March - Therapeutic Areas and 11 March - Record date for Product Portfolio 20 Directors' Report interim dividend Innovation 26 Remuneration Report 77 9 April - Interim dividend paid 30 June - Full Year ends Financial Report 19 August - Annual profit and final dividend announcement Financial Report 106 9 September - Shares trade ex-dividend Shareholder Information

CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.

46 Unvested Rights represent Tranche 2 of the 2023 grant that will vest on 21 August 2023, following the release of full year financial results.

Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

We look forward to sharing the full results of our phase 3 study in the coming months.

Eyo, who received an Uplifting Athletes grant to research SLC6A1, gives an update on his work and gives credit to the mom of a 5-year-old boy who personally recruited him..